|
Zinc deficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The resulting Zn deficiency leads, through its metalloenzymes, to a low NAP activity and depressed DNA & RNA polymerase activities: the latter necessitates an adaptive mechanism to sustain cell division despite low zinc.
|
7666834 |
1995 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, rMBP-NAP also showed significant anti-angiogenic activity by reducing vascularization in lung tumor sections. rMBP-NAP could induce antitumor immunity through activating Th1 cells and producing pro-inflammatory cytokines, which are responsible for the effective cytotoxic immune response against cancer progression.
|
28863272 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Functional characterization revealed that CTNNBL1 promoted the proliferation and invasion of ovarian cancer cells in vitro.
|
28501461 |
2017 |
|
Tuberculosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 1431 acid-fast bacilli (AFB) in Bactec culture vials from 1427 patients was differentiated by the Bactec NAP method and tested by the LCx Mycobacterium tuberculosis ligase chain reaction system.
|
12171305 |
2002 |
|
Tauopathies
|
0.020 |
Biomarker
|
group |
BEFREE |
Here, we examined the potential preferential interaction of NAP with 3R vs. 4R Tau, toward personalized treatment of tauopathies.
|
30865715 |
2019 |
|
Tauopathies
|
0.020 |
Biomarker
|
group |
BEFREE |
We previously investigated the disease-modifying potential of a microtubule-stabilising peptide NAP (NAPVSIPQ) in a well-established Drosophila model of tauopathy characterised by microtubule breakdown and axonal transport deficits.
|
27910888 |
2016 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Infection with virulent H pylori strains secreting HP-NAP is associated with severe gastroduodenal diseases, and HP-NAP may play a role in the development of gastric carcinoma. rHP-NAP-based ELISA can be used as a new method to detect H pylori infection.
|
19452583 |
2009 |
|
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the present work, we attempt to elucidate the effect of rMBP-NAP at the local immune modulation in B16-F10-induced metastatic lung cancer.
|
28863272 |
2018 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.
|
26553741 |
2015 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Label-free quantification of EVs was performed to identify differentially expressed proteins between PCa and NAP.
|
31018022 |
2019 |
|
Progressive supranuclear palsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinically, NAP (davunetide, CP201) exhibited efficacy in prodromal Alzheimer's disease patients (Tau3R/4R tauopathy) but not in progressive supranuclear palsy (increased Tau4R tauopathy).
|
30865715 |
2019 |
|
Prodromal Alzheimer's disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinically, NAP (davunetide, CP201) exhibited efficacy in prodromal Alzheimer's disease patients (Tau3R/4R tauopathy) but not in progressive supranuclear palsy (increased Tau4R tauopathy).
|
30865715 |
2019 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer.
|
30214604 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Down-regulation of a novel gene, DRLM, in human liver malignancy from 4q22 that encodes a NAP-like protein.
|
12383514 |
2002 |
|
Pheochromocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pheochromocytoma cells (PC12), exposed to high concentration of zinc (400µM), were used to determine the protective effect of NAP on Tau phosphorylation and two Tau kinases (Fyn and GSK-3β).
|
30417779 |
2018 |
|
Periapical Periodontitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The maintenance of AP in molar teeth with necrotic pulp and apical periodontitis was associated with less postoperative pain when compared with NAP.
|
29370942 |
2018 |
|
Parkinson Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results reveal that A53T α-synuclein (oligomers or aggregates) leads to the inhibition of mitochondrial trafficking, which can be rescued by NAP, suggesting the involvement of microtubule disruption in the pathophysiology of Parkinson's disease.
|
27866262 |
2017 |
|
Pain, Postoperative
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The maintenance of AP in molar teeth with necrotic pulp and apical periodontitis was associated with less postoperative pain when compared with NAP.
|
29370942 |
2018 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.
|
28501461 |
2017 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
LHGDN |
Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
|
19148501 |
2009 |
|
Obesity, Morbid
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In case-control studies neither of the CTNNBL1 variants showed association with overweight, obesity or morbid obesity (rs6013029: Odds Ratio (OR)(overweight) = 1.02 [0.90-1.16], OR(obesity) = 1.09 [0.95-1.25], OR(morbidobesity) = 1.26 [0.91-1.74]; rs6020846: OR(overweight) = 1.05 [0.93-1.18], OR(obesity) = 1.13 [1.00-1.28], OR(morbidobesity) = 1.17 [0.86-1.61]).
|
19245693 |
2009 |
|
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In case-control studies neither of the CTNNBL1 variants showed association with overweight, obesity or morbid obesity (rs6013029: Odds Ratio (OR)(overweight) = 1.02 [0.90-1.16], OR(obesity) = 1.09 [0.95-1.25], OR(morbidobesity) = 1.26 [0.91-1.74]; rs6020846: OR(overweight) = 1.05 [0.93-1.18], OR(obesity) = 1.13 [1.00-1.28], OR(morbidobesity) = 1.17 [0.86-1.61]).
|
19245693 |
2009 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity.
|
18325910 |
2008 |
|
Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We found no evidence for an association of the reported variants in CTNNBL1 with early onset obesity or increased BMI.
|
19228371 |
2009 |
|
Neuroendocrine Tumors
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we armed a replication-selective, infection-enhanced adenovirus with secretory HP-NAP, Ad5PTDf35-[Δ24-sNAP], and evaluated its therapeutic efficacy against neuroendocrine tumors.
|
23817216 |
2013 |